| Name | Title | Contact Details |
|---|
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.
JDS Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alta Analytical Laboratory is a El Dorado Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.
RareMed Solutions offers comprehensive support services for specialty, orphan and ultra-orphan products. Our team has a breadth of experience developing and maintaining therapy specific solutions to ensure compliance. RareMed Solutions is the ideal partner for biotech firms and pharmaceutical manufacturers due to our custom solutions that are unique to each of our partner’s needs. RareMed Solutions is committed to providing the highest level of care to patients we serve. We offer specialized, highly-customizable services designed to increase patient access, affordability, and adherence to therapy. The extensive experience and unmatched service delivery translates to the best possible care for patients as well as enhancing product performance.